Fig. 8

Forest plots of the pooled RRs for the ORR, disease control, and grade 3 or higher hematological (including neutropenia, and anemia) and non-hematological (including pneumonia, diarrhea, and fatigue) adverse events of the patients with MM in the MAbs targeting PD-1/PD-L1 group versus control group. The RRs for the ORR and disease control > 1 favour the MAb group. The RRs for the incidence of adverse events < 1 favour the MAb group. The size of the blocks or diamonds represents the weight of the fixed effects model in the meta-analysis